%0 Generic %A P., Balasubramanian %A E., Chendamarai %A P., Markose %A L., Fletcher %A S., Branford %A B., George %A V., Mathews %A M., Chandy %A A., Srivastava %D 2012 %T Supplementary Material for: International Reporting Scale of BCR-ABL1 Fusion Transcript in Chronic Myeloid Leukemia: First Report from India %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_International_Reporting_Scale_of_i_BCR-ABL1_i_Fusion_Transcript_in_Chronic_Myeloid_Leukemia_First_Report_from_India/5123104 %R 10.6084/m9.figshare.5123104.v1 %2 https://ndownloader.figshare.com/files/8708677 %2 https://ndownloader.figshare.com/files/8708680 %K Chronic myeloid leukemia %K Complete cytogenetic response %K BCR-ABL1 transcripts %K Major molecular response %X Achieving a major molecular response (MMR) is an important predictor of progression-free survival in chronic myeloid leukemia patients treated with imatinib. This requires accurate measurement of BCR-ABL1 transcripts normalized to a control gene, as well as defining a level (BCR-ABL1/control gene ratio) that will correlate with sustained clinical response. To make these measurements comparable between laboratories, an international scale (IS) is necessary. A BCR-ABL1/control gene ratio of 0.10% represents MMR in the IS. In collaboration with an international reference laboratory in Adelaide, S.A., Australia, we have established and validated a lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS. In this report, we explain the process and steps involved in obtaining a valid lab-specific conversion factor for expressing BCR-ABL1 transcript levels in the IS. %I Karger Publishers